Inactivated rabies-vectored SARS-CoV-2 vaccine provides long-term immune response unaffected by vector immunity
Abstract The objective of this study is to further analyze recombinant rabies virus-vectored SARS-CoV-2 vaccine, CORAVAX, as an effective COVID-19 vaccine strategy. CORAVAX has proven immunogenic and protective against SARS-CoV-2 in animal models. Here, we have screened adjuvants for the highest qua...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-09-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-022-00532-7 |
| _version_ | 1797642142845239296 |
|---|---|
| author | Catherine Yankowski Christoph Wirblich Drishya Kurup Matthias J. Schnell |
| author_facet | Catherine Yankowski Christoph Wirblich Drishya Kurup Matthias J. Schnell |
| author_sort | Catherine Yankowski |
| collection | DOAJ |
| description | Abstract The objective of this study is to further analyze recombinant rabies virus-vectored SARS-CoV-2 vaccine, CORAVAX, as an effective COVID-19 vaccine strategy. CORAVAX has proven immunogenic and protective against SARS-CoV-2 in animal models. Here, we have screened adjuvants for the highest quality antibody titers, negated the concern of pre-existing rabies-vector immunity, and established its potential as a long-term COVID-19 vaccine. We have tested toll-like receptor 4 (TLR4) agonists, inflammasome activators, and alum adjuvants in CORAVAX and found TLR4-activating MPLA-AddaVax to have the greatest potential. We followed the humoral immune response to CORAVAX in mice with pre-existing rabies virus immunity and saw no significant differences compared to naive mice. We then followed the immune response to CORAVAX over several months and 1-year post-immunization. Mice maintained high antigen-specific serum antibody titers as well as long-lived antibody-secreting cells in the spleen and bone marrow. We believe this rabies-vector strategy combats the problem of waning immunity of other COVID-19 vaccines. These results together support CORAVAX’s potential during the ongoing COVID-19 pandemic. |
| first_indexed | 2024-03-11T13:55:55Z |
| format | Article |
| id | doaj.art-2752e4a5f5ff490aa1b582118b8383c9 |
| institution | Directory Open Access Journal |
| issn | 2059-0105 |
| language | English |
| last_indexed | 2024-03-11T13:55:55Z |
| publishDate | 2022-09-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Vaccines |
| spelling | doaj.art-2752e4a5f5ff490aa1b582118b8383c92023-11-02T06:36:40ZengNature Portfolionpj Vaccines2059-01052022-09-017111110.1038/s41541-022-00532-7Inactivated rabies-vectored SARS-CoV-2 vaccine provides long-term immune response unaffected by vector immunityCatherine Yankowski0Christoph Wirblich1Drishya Kurup2Matthias J. Schnell3Department of Microbiology and Immunology, Sidney Kimmel Medical College at Thomas Jefferson UniversityDepartment of Microbiology and Immunology, Sidney Kimmel Medical College at Thomas Jefferson UniversityDepartment of Microbiology and Immunology, Sidney Kimmel Medical College at Thomas Jefferson UniversityDepartment of Microbiology and Immunology, Sidney Kimmel Medical College at Thomas Jefferson UniversityAbstract The objective of this study is to further analyze recombinant rabies virus-vectored SARS-CoV-2 vaccine, CORAVAX, as an effective COVID-19 vaccine strategy. CORAVAX has proven immunogenic and protective against SARS-CoV-2 in animal models. Here, we have screened adjuvants for the highest quality antibody titers, negated the concern of pre-existing rabies-vector immunity, and established its potential as a long-term COVID-19 vaccine. We have tested toll-like receptor 4 (TLR4) agonists, inflammasome activators, and alum adjuvants in CORAVAX and found TLR4-activating MPLA-AddaVax to have the greatest potential. We followed the humoral immune response to CORAVAX in mice with pre-existing rabies virus immunity and saw no significant differences compared to naive mice. We then followed the immune response to CORAVAX over several months and 1-year post-immunization. Mice maintained high antigen-specific serum antibody titers as well as long-lived antibody-secreting cells in the spleen and bone marrow. We believe this rabies-vector strategy combats the problem of waning immunity of other COVID-19 vaccines. These results together support CORAVAX’s potential during the ongoing COVID-19 pandemic.https://doi.org/10.1038/s41541-022-00532-7 |
| spellingShingle | Catherine Yankowski Christoph Wirblich Drishya Kurup Matthias J. Schnell Inactivated rabies-vectored SARS-CoV-2 vaccine provides long-term immune response unaffected by vector immunity npj Vaccines |
| title | Inactivated rabies-vectored SARS-CoV-2 vaccine provides long-term immune response unaffected by vector immunity |
| title_full | Inactivated rabies-vectored SARS-CoV-2 vaccine provides long-term immune response unaffected by vector immunity |
| title_fullStr | Inactivated rabies-vectored SARS-CoV-2 vaccine provides long-term immune response unaffected by vector immunity |
| title_full_unstemmed | Inactivated rabies-vectored SARS-CoV-2 vaccine provides long-term immune response unaffected by vector immunity |
| title_short | Inactivated rabies-vectored SARS-CoV-2 vaccine provides long-term immune response unaffected by vector immunity |
| title_sort | inactivated rabies vectored sars cov 2 vaccine provides long term immune response unaffected by vector immunity |
| url | https://doi.org/10.1038/s41541-022-00532-7 |
| work_keys_str_mv | AT catherineyankowski inactivatedrabiesvectoredsarscov2vaccineprovideslongtermimmuneresponseunaffectedbyvectorimmunity AT christophwirblich inactivatedrabiesvectoredsarscov2vaccineprovideslongtermimmuneresponseunaffectedbyvectorimmunity AT drishyakurup inactivatedrabiesvectoredsarscov2vaccineprovideslongtermimmuneresponseunaffectedbyvectorimmunity AT matthiasjschnell inactivatedrabiesvectoredsarscov2vaccineprovideslongtermimmuneresponseunaffectedbyvectorimmunity |